The Japanese biopharmaceutical company saw its total revenue fall to ¥18.52 billion, down significantly from ¥46.68 billion in the prior period. This decline led to an operating loss of ¥5.01 billion, contrasted with an operating profit of ¥21.11 billion a year earlier, according to the financial results released under IFRS accounting standards.

Deepening Fiscal Pressure

The downturn impacted all levels of the company's balance sheet, with the pretax loss reaching ¥5.31 billion. On a per-share basis, the company recorded a loss of ¥28.99, a stark shift from the ¥115.85 earnings per share reported in the previous fiscal cycle.

Key performance metrics for the period ended December 31 include:

• A net loss of ¥3.75 billion compared to a ¥15.01 billion profit the year prior.
• A drop in revenue to ¥18.52 billion from ¥46.68 billion.
• An operating loss of ¥5.01 billion versus a prior-year profit of ¥21.11 billion.